Payment overview · 2025
General Payments
$561.31
24 reported records · 13 companies
Healthcare provider profile · identity verified
Alan Johnstone Paysinger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEWBERRY, SC · NPI 1568470326
Verified facts
What the public records show
CMS Open Payments records show Alan Johnstone Paysinger, MD received $561.31 in general payments during 2025 across 24 reported records.
Corcept Therapeutics accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $185.16 | 33.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $63.19 | 11.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.43 | 8.6% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $43.66 | 7.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.31 | 7.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.15 | 6.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.74 | 5.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.97 | 5.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.97 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.53 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.37 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.61 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.31 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $185.16 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $63.19 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $43.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.31 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.15 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 591 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 137 |
| Losartan Potassium | Losartan Potassium | 477 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 100 |
| Omeprazole | Omeprazole | 448 | 106 |
| Metformin Hcl | Metformin Hcl | 405 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 81 |
| Lisinopril | Lisinopril | 350 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 91 |
| Famotidine | Famotidine | 308 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 300 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 68 |
| Gabapentin | Gabapentin | 251 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 72 |
| Simvastatin | Simvastatin | 236 | 62 |
| Furosemide | Furosemide | 229 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 42 |
| Eliquis | Apixaban | 202 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 199 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 196 | 53 |
| Allopurinol | Allopurinol | 165 | 38 |
| Ozempic | Semaglutide | 163 | 27 |
| Tramadol Hcl | Tramadol Hcl | 160 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 42 |
| Potassium Chloride | Potassium Chloride | 146 | 38 |
| Jardiance | Empagliflozin | 131 | 29 |
| Lorazepam | Lorazepam | 127 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 119 | 25 |
| Montelukast Sodium | Montelukast Sodium | 115 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 21 |
| Azithromycin | Azithromycin | 104 | 79 |
| Trazodone Hcl | Trazodone Hcl | 104 | 28 |
| Benazepril Hcl | Benazepril Hcl | 100 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 21 |
| Meloxicam | Meloxicam | 96 | 29 |
| Alprazolam | Alprazolam | 91 | 24 |
| Clonazepam | Clonazepam | 91 | 15 |
| Donepezil Hcl | Donepezil Hcl | 89 | 22 |
| Januvia | Sitagliptin Phosphate | 89 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 21 |
| Metformin Hcl Er | Metformin Hcl | 75 | 21 |
| Prednisone | Prednisone | 75 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 21 |
| Sertraline Hcl | Sertraline Hcl | 73 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 72 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 19 |
| Atenolol | Atenolol | 67 | 17 |
| Carvedilol | Carvedilol | 67 | 20 |
| Farxiga | Dapagliflozin Propanediol | 67 | 15 |
| Memantine Hcl | Memantine Hcl | 66 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 16 |
| Bupropion Xl | Bupropion Hcl | 61 | 12 |
| Alendronate Sodium | Alendronate Sodium | 55 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 17 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 12 |
| Glimepiride | Glimepiride | 48 | 13 |
| Irbesartan | Irbesartan | 47 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 42 |
| Diazepam | Diazepam | 45 | suppressed |
| Lovastatin | Lovastatin | 45 | 12 |
| Cefuroxime | Cefuroxime Axetil | 44 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Finasteride | Finasteride | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 13 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | 13 |
| Spironolactone | Spironolactone | 33 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.31 · 24 records | Corcept Therapeutics | ABRYSVO, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INJECTAFER, JARDIANCE, Kerendia, Korlym, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error